Online citations, reference lists, and bibliographies.
← Back to Search

Effects Of The Combination Of Camptothecin And Doxorubicin Or Etoposide On Rat Glioma Cells And Camptothecin-resistant Variants

V. Pavillard, D. Kherfellah, S. Richard, J. Robert, D. Montaudon
Published 2001 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
From the rat C6 glioma cell line in culture, we selected camptothecin-resistant variants by growth in the presence of increasing amounts of this drug (C6CPT10, C6CPT50 and C6CPT100, growing respectively with 10, 50 and 100 ng ml–1 camptothecin). The degree of resistance to camptothecin ranged between 15-fold (C6CPT10) and 30-fold (C6CPT50and C6CPT100). The C6CPT10 cell line presented a collateral sensitivity to etoposide (3.6-fold), while the C6CPT50 and C6CPT100 cell lines were cross-resistant to etoposide (1.8-fold) The resistant lines were characterised by a two-fold reduced content and catalytic activity of topoisomerase I, and C6CPT50 and C6CPT100 presented a significant increase in topoisomerase IIα content and catalytic activity and a marked overexpression of P-glycoprotein. We explored the cytotoxicity of combinations of a topoisomerase I inhibitor (camptothecin) and a topoisomerase II inhibitor (doxorubicin or etoposide) at several molar ratios, allowing the evaluation of their synergistic or antagonistic effects on cell survival using the median effect principle. The simultaneous combination of camptothecin and doxorubicin or etoposide was additive or antagonistic in C6 cells, slightly synergistic in the C6CPT10 line and never more than additive in the C6CPT50 and C6CPT100 cell lines. The sequential combination of doxorubicin and camptothecin gave additivity in the order camptothecin → doxorubicin and antagonism in the order doxorubicin → camptothecin. Clinical protocols combining a topoisomerase I and a topoisomerase II inhibitor should be considered with caution because antagonistic effects have been observed with combinations of camptothecin and doxorubicin. © 2001 Cancer Research Campaign http://www.bjcancer.com
This paper references
10.1016/0959-8049(92)90107-D
Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells.
R. Bertrand (1992)
10.1097/00001813-199708000-00005
Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro
M. Stahl (1997)
10.1016/S1054-3589(08)61133-3
Drug resistance mechanisms of topoisomerase I drugs.
T. Andoh (1994)
Dose-effect analysis with microcomputers
J Chou (1987)
10.1038/bjc.1997.585
Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
V. M. Herben (1997)
10.1016/S1054-3589(08)61132-1
Mechanisms of topoisomerase I inhibition by anticancer drugs.
Y. Pommier (1994)
10.1016/S1054-3589(08)60537-2
DNA topoisomerases as targets of therapeutics: an overview.
J. Wang (1994)
10.1038/227680A0
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
U. Laemmli (1970)
Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
S. Kaufmann (1991)
10.1111/J.1432-1033.1997.00307.X
Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells.
D. Montaudon (1997)
10.1146/ANNUREV.BI.58.070189.001033
The biochemistry of P-glycoprotein-mediated multidrug resistance.
J. A. Endicott (1989)
10.1146/ANNUREV.BI.58.070189.002031
DNA topoisomerase poisons as antitumor drugs.
L. Liu (1989)
10.1016/S1054-3589(08)60542-6
Roles of DNA topoisomerases in chromosomal replication and segregation.
J. Nitiss (1994)
10.1016/0163-7258(91)90022-E
Principles and practice of DNA filter elution.
K. Kohn (1991)
10.1093/JNCI/81.22.1732
Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
K. B. Tan (1989)
10.1126/science.161.3839.370
Differentiated Rat Glial Cell Strain in Tissue Culture
P. Benda (1968)
Phase I and © 2001 Cancer Research Campaign pharmacological study of sequential intravenous topotecan and oral etoposide
Herben VMM (1997)
10.1093/JNCI/82.7.607
Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro.
B. Hill (1990)
Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line.
N. Masumoto (1995)
10.1007/s002800050545
The significance of the sequence of administration of topotecan and etoposide
J. Bonner (1996)
10.1002/IJC.2910490423
Multifactorial resistance in LS174T human colon carcinoma cells selected with doxorubicin
M. J. Rabier (1991)
10.1038/bjc.1997.584
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
M. Ando (1997)
Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells.
A. Y. Chen (1991)
Biosoft: Cambridge Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effect of multiple drugs or enzyme inhibitors
J Chou (1987)
10.1016/0065-2571(84)90007-4
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.
T. Chou (1984)
10.1093/JNCI/85.8.632
Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs.
P. M. Chaudhary (1993)
10.1016/S1054-3589(08)61134-5
Mechanism of action of topoisomerase II-targeted antineoplastic drugs.
N. Osheroff (1994)
10.1016/0753-3322(90)90026-6
Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines.
M. Oguro (1990)
Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines.
Y. Sugimoto (1990)
10.1038/bjc.1992.111
P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines.
S. Huet (1992)
10.1016/S0300-9084(98)80007-2
Drug resistance to topoisomerase II inhibitors.
J. Robert (1998)
10.1016/S1054-3589(08)60541-4
The DNA binding, cleavage, and religation reactions of eukaryotic topoisomerases I and II.
A. Andersen (1994)
10.1073/PNAS.78.6.3487
Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei.
L. Liu (1981)



This paper is referenced by
10.1021/mp500744m
Synergistically Enhanced Therapeutic Effect of a Carrier-Free HCPT/DOX Nanodrug on Breast Cancer Cells through Improved Cellular Drug Accumulation.
F. Chen (2015)
10.1080/10717544.2018.1472678
Preparation of a mesoporous silica-based nano-vehicle for dual DOX/CPT pH-triggered delivery
Maria C. Llinàs (2018)
10.1007/978-1-4614-2305-8_6
Versatile Fixed-Ratio Drug Combination Delivery Using Hydrophobic Prodrug Nanoparticles
Barry D. Liboiron (2012)
10.1016/j.jacbts.2018.06.005
Role of Endothelium in Doxorubicin-Induced Cardiomyopathy
Albert Z Luu (2018)
10.1158/1535-7163.MCT-06-0118
Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice
L. Mayer (2006)
Local delivery of doxorubicin for the treatment of malignant brain tumors in rats.
M. Lesniak (2005)
10.1007/s00280-014-2418-8
A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
T. Shoji (2014)
10.1080/17474086.2017.1369400
CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?
C. Brunetti (2017)
10.1586/14737140.8.5.707
Topoisomerase I inhibitors for the treatment of brain tumors
L. Feun (2008)
10.1124/MI.7.4.8
Optimizing combination chemotherapy by controlling drug ratios.
L. Mayer (2007)
10.1017/S0317167100004753
MR-pathological comparison in F98-Fischer glioma model using a human gantry.
J. Blanchard (2006)
Functionalization of nanocarriers for efficient combination drug delivery
C. Hu (2011)
Exploiting Drug Ratio – Dependent Informatics : Nano-Scale Delivery Vehicles In Vivo
L. Mayer (2007)
10.1021/am402082d
One-pot construction of functional mesoporous silica nanoparticles for the tumor-acidity-activated synergistic chemotherapy of glioblastoma.
Ze-yong Li (2013)
Affinity-based Delivery and Reloading of Doxorubicin For Treatment of Glioblastoma Multiforme
Andrew S. Fu (2013)
10.1039/c4nr03514c
Polysaccharide nano-vesicular multidrug carriers for synergistic killing of cancer cells.
P. S. Pramod (2014)
10.1021/acs.molpharmaceut.7b00219
A Nano-in-Nano Polymer-Dendrimer Nanoparticle-Based Nanosystem for Controlled Multidrug Delivery.
Zongmin Zhao (2017)
10.1016/B978-0-323-42863-7.00008-6
Nanoparticles as drug delivery systems of combination therapy for cancer
Yuannian Zhang (2016)
10.1039/C5MD00365B
Multi-drug delivery nanocarriers for combination therapy
Suresh Gadde (2015)
10.3816/CCC.2002.N.023
Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
J. Xu (2002)
10.1002/wnan.1264
Recent progress in the development of polysaccharide conjugates of docetaxel and paclitaxel.
Aniruddha Roy (2014)
10.1002/9783527634057.CH31
Nanoscale Delivery Systems for Combination Chemotherapy
Barry D. Liboiron (2011)
10.1016/j.jconrel.2015.04.031
Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.
K. Camacho (2015)
10.1007/s10856-009-3803-4
Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model
S. Baltes (2010)
10.1038/srep06064
Multifunctional Enveloped Mesoporous Silica Nanoparticles for Subcellular Co-delivery of Drug and Therapeutic Peptide
Guo-feng Luo (2014)
10.1021/acs.molpharmaceut.5b00544
Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission.
Y. Jiang (2015)
10.3389/fneur.2018.00459
Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy
Amol Mehta (2018)
10.1038/sj.leu.2402621
Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines
W. Liu (2002)
10.1016/j.leukres.2008.06.028
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.
P. Tardi (2009)
10.1016/j.bcp.2012.01.008
Nanoparticle-based combination therapy toward overcoming drug resistance in cancer.
C. Hu (2012)
10.1039/c5bm00268k
Stimuli-responsive polymersomes for cancer therapy.
T. Thambi (2016)
10.1016/j.pharmthera.2008.11.003
Pharmacotherapy for adults with tumors of the central nervous system.
Nina Felice Schor (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar